FourKites Bolsters its Management Team with Supply Chain Industry Veterans
19.1.2023 11:00:00 EET | Business Wire | Press release
Leading supply chain visibility company FourKites today announces it has strengthened its executive team with the appointment of a Chief Strategy Officer and a Vice President of Global Customer Success. FourKites’ leadership position, rapid growth and momentum in the supply chain visibility market continue to make it a destination for top talent in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005040/en/
FourKites Bolsters its Management Team with Supply Chain Industry Veterans (Photo: Business Wire)
Fabrizio (Fab) Brasca has been promoted to FourKites Chief Strategy Officer. Brasca joined FourKites last year as EVP, Industry and Market Strategy. As Chief Strategy Officer, he will continue to lead the company’s Industry teams and take on expanded responsibilities including the strategy for FourKites’ Global Alliances division and leadership of the customer value engineering and pre-sales functions.
Additionally, Rebecca Nerad joined FourKites as Vice President of Global Customer Success. Nerad has over 20 years of experience in the supply chain industry, holding customer success roles for companies such as i2 Technologies, JDA Software and Bristlecone. Most recently, she served as Vice President of Customer Success at e2open, maximising solution adoption, expansion and retention. Nerad and her team will remain focused on building strong relationships and driving value with customers as FourKites expands.
“Fab has played a pivotal role in establishing FourKites’ industry team and building a vertical go-to-market strategy. His industry knowledge and partnership with customers will serve him well as he helps FourKites develop and execute its strategy more broadly,” says FourKites founder and CEO Mathew Elenjickal. “And Rebecca is a remarkable talent and a great fit for our culture, where we pride ourselves on true partnership with our customers. I look forward to working with both of them, as we continue toward our goal of helping customers achieve 100% visibility everywhere.”
FourKites continues to attract top-level talent from the industry as it gains recognition as a great place to work and a pioneering innovator in the real-time visibility market. This month, FourKites was named to Built In’s list of Best Places to Work in Chicago for the third consecutive year, and it has been named a Great Place to Work in India by the Great Places Institute for five consecutive years. The company has been recognised for its ability to solve the complex pain points of enterprise customers, having been named a Leader in Gartner’s Magic Quadrant for Real-time Transportation Visibility Platforms for its ability to execute, and with the highest completeness of vision. FourKites also scored the highest for Fortune 500 businesses with complex needs, according to Gartner’s Critical Capabilities for Real-Time Transportation Visibility Platforms report. Other accolades include Inc. Magazine’s Best in Business list in the Logistics & Transportation category, AI Trailblazer by Everest Group, the 2022 Top Food Chain Technology providers, Top Green Provider, and BlueYonder's GTM Partner of the Year in 2022.
About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005040/en/
Contact information
Scott Johnston
European PR Director, FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom